Abstract: The present invention relates a composition comprising Diclofenac and salts thereof wherein Diclofenac or its salts are present in an amount of 25-200 mg. The composition is suitable for the parenteral administration through intramuscular, intravenous route; also for oral, dermal, subcutaneous, cutaneous, nasal, ocular drops, as rectal suppository, vaginal pessaries, intra-articular, and otic delivery. The invention also provides compositions comprising a combination of Diclofenac and other drugs. The invention further provides a method for preparing said composition.

Abstract: A system and method of dynamically generating ticket barcodes for ticket orders is disclosed. A ticket order including tickets related to an event may be received from an article dispensing machine or another source. Random barcodes can be generated as the basis for the ticket barcodes. The ticket barcodes can be generated based on barcode attributes unique to a ticket supplier or a venue of the event. Such barcode attributes can include a barcode prefix, a barcode suffix, a barcode total length, and a barcode symbology. When the tickets in a ticket order are ready to be produced, images of the ticket barcodes can be generated and assigned based on the barcode attributes. The user experience for purchasing tickets from disparate ticket suppliers and/or venues can accordingly be simplified and streamlined.

Abstract: A drill stem test string may include a tubular body having an axial bore formed at least partially therethrough. An axial flow valve may be coupled to the first tubular body and allow fluid to flow axially through the first tubular body when in an open state and prevent fluid from flowing axially through the first tubular body when in a closed state. A radial flow valve may be coupled to the first tubular body and allow fluid to flow radially through the first tubular body when in an open state and prevent fluid from flowing radially through the first tubular body when in a closed state. A seal assembly may be coupled to an outer surface of the first tubular body and positioned between a lower end of the first tubular member and the first radial flow valve.

Abstract: A technique that is usable with a well includes deploying a plurality of location markers in a passageway of the well and deploying an untethered object in the passageway such that the object travels downhole via the passageway. The technique includes using the untethered object to sense proximity of at least some of the location markers as the object travels downhole, and based on the sensing, selectively expand its size to cause the object to become lodged in the passageway near a predetermined location.

Abstract: A system or method includes providing coupler portions along a structure. The coupler portions are communicatively engageable with equipment in the structure.

Abstract: A technique facilitates controlling fluid flows, such as fluid flows in a downhole well zone or zones. A flow control valve is employed to control a fluid flow and is operationally linked with an injection valve. Actuation of the flow control valve is used to automatically actuate the injection valve between corresponding positions allowing or blocking fluid injection. Closing or opening of the flow control valve thus results in a desired corresponding action of the injection valve, such as blocking flow or allowing flow through the injection valve.

Abstract: In one aspect, the present invention features a tablet including: (i) a first drug layer including naproxen; (ii) a second drug layer including a decongestant (e.g., pseudoephedrine) wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours; and (iii) a barrier layer that does not include naproxen, wherein the barrier layer is in contact with the first drug layer; and (iv) a third drug layer including cetirizine, wherein the third drug layer is in contact with the barrier layer and is not in contact with the first drug layer.

Abstract: A retrievable flow control device comprising a housing configured to sealably couple with a completion component. The housing may comprise a first port and a second port establishing a fluid pathway. The fluid pathway may regulate a fluid flow as the fluid flow passes through the fluid pathway. The housing may further comprise a coupling mechanism configured to releasably couple with a corresponding feature of the wellbore completion. The downhole flow control device may be configured to be retrievable independently of the completion component. The flow control device may comprise a check valve in the fluid pathway in order to substantially constrain the fluid flow to a single direction. In some cases, the flow control device may be configured to couple with a side pocket. In other cases, a concentric flow control device may be configured to couple with a screen base pipe, tubing, or stinger.

Abstract: A technique facilitates controlling flow of fluid along a flow passage. A flow control assembly is placed along a flow passage, and a bypass is routed past the flow control assembly. Flow along the bypass is controlled by a flow bypass mechanism which may be operated via a pressure or other interventionless application. The pressure, or other interventionless application, is used to actuate the flow bypass mechanism so as to selectively allow flow through the bypass.

Abstract: In one aspect, the present invention features a tablet including a first drug layer, a second drug layer, and a third drug layer, wherein (i) the first drug layer includes naproxen; (ii) a second drug layer including pseudoephedrine; and (iii) the third drug layer includes cetirizine; wherein the first drug layer is in contact with the second drug layer, the third drug layer is in contact with the second drug layer, and the first drug layer is not in contact with the third drug layer, and wherein the second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours.

Abstract: A technique includes running a lower completion assembly into a well in a single trip. The lower completion assembly includes a screen, a first valve and a second valve. The technique includes performing a gravel packing operation using the lower completion assembly, where performing the gravel packing operation includes running a service assembly into the lower completion assembly to operate the first valve. The technique further includes removing the service assembly from the well and subsequently installing an upper completion assembly in the well. The installation of the upper completion assembly enables remote control of the second valve of the lower completion assembly for purposes of regulating the production of fluid from the well.

Abstract: A technique provides a system and methodology for enhancing the operational life of an electric submersible pumping system. A completion is combined with a flow diverter valve and is positioned downhole in a wellbore. An electric submersible pumping system is coupled into the completion and the flow diverter valve is oriented to control fluid flow with respect to the electric submersible pumping system. For example, the flow diverter valve may be automatically operable to direct well fluid to the electric submersible pumping system when the pumping system is operating and to direct well fluid to bypass the electric submersible pumping system when the pumping system is not operating.

Abstract: A technique is provided to facilitate use of a service tool at a downhole location. The service tool has different operational configurations that can be selected and used without moving the service string.

Abstract: The present invention is directed to methods of treating eye disease. In one embodiment, the method can comprise administering a bioconjugate to a subject to treat the eye disease, where the bioconjugate comprises a taxane covalently bonded to a cobalamin. Additionally, the bioconjugate can be dissolved in an aqueous solution prior to administration.

Abstract: The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies including anti-angiogenic chemotherapies, alone or in combination with other anti-cancer/anti-angiogenic compounds.

Abstract: A technique facilitates use and installation of a large bore completion system. The technique comprises providing infrastructure during an initial completion stage and deploying a monitoring system. Based on data from the monitoring system, an intelligent completion may later be deployed as necessary to control production, injection, or other well related fluid flows.

Abstract: The present invention is directed to methods of treating eye disease. In one embodiment, the method can comprise administering a taxane-cobalamin bioconjugate or another taxane compound to a subject to treat the eye disease. In one embodiment, the bioconjugate can be dissolved in an aqueous solution prior to administration.

Abstract: An installation system and method configured to install a lower completion section is provided. The installation system may comprise an installation drill pipe configured to releasably couple with a lower completion section. The installation system may comprise an electrical wet connect. The electrical wet connect may be coupled with a connector configured to establish a communication pathway between the electrical wet connect and components of the lower completion section. The lower completion section may be run in hole. Communications between a surface location and the lower completion components may be established via the electrical wet connect. The lower completion components may be tested prior to setting a lower completion section packer.

Abstract: In one aspect, the present invention features a tablet including a first drug layer, a second drug layer, and a third drug layer, wherein (i) the first drug layer includes naproxen; (ii) a second drug layer including pseudoephedrine; and (iii) the third drug layer includes cetirizine; wherein the first drug layer is in contact with the second drug layer, the third drug layer is in contact with the second drug layer, and the first drug layer is not in contact with the third drug layer, and wherein the second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours.

Abstract: In one aspect, the present invention features a tablet including: (i) a first drug layer including naproxen; (ii) a second drug layer including a decongestant (e.g., pseudoephedrine) wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours; and (iii) a barrier layer that does not include naproxen, wherein the barrier layer is in contact with the first drug layer; and (iv) a third drug layer including cetirizine, wherein the third drug layer is in contact with the barrier layer and is not in contact with the first drug layer.